BibTex format
@article{Patchsung:2022:10.1089/crispr.2022.0048,
author = {Patchsung, M and Homchan, A and Aphicho, K and Suraritdechachai, S and Wanitchanon, T and Pattama, A and Sappakhaw, K and Meesawat, P and Wongsatit, T and Athipanyasilp, A and Jantarug, K and Athipanyasilp, N and Buahom, J and Visanpattanasin, S and Niljianskul, N and Chaiyen, P and Tinikul, R and Wichukchinda, N and Mahasirimongkol, S and Sirijatuphat, R and Angkasekwinai, N and Crone, MA and Freemont, PS and Joung, J and Ladha, A and Abudayyeh, O and Gootenberg, J and Zhang, F and Chewapreecha, C and Chanarat, S and Horthongkham, N and Pakotiprapha, D and Uttamapinant, C},
doi = {10.1089/crispr.2022.0048},
journal = {The CRISPR Journal},
pages = {1--17},
title = {A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance},
url = {http://dx.doi.org/10.1089/crispr.2022.0048},
volume = {6},
year = {2022}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - Point-of-care (POC) nucleic acid detection technologies are poised to aid gold-standard technologies in controlling the COVID-19 pandemic, yet shortcomings in the capability to perform critically needed complex detection—such as multiplexed detection for viral variant surveillance—may limit their widespread adoption. Herein, we developed a robust multiplexed clustered regularly interspaced short palindromic repeats (CRISPR)-based detection using LwaCas13a and PsmCas13b to simultaneously diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and pinpoint the causative SARS-CoV-2 variant of concern (VOC)—including globally dominant VOCs Delta (B.1.617.2) and Omicron (B.1.1.529)—all the while maintaining high levels of accuracy upon the detection of multiple SARS-CoV-2 gene targets. The platform has several attributes suitable for POC use: premixed, freeze-dried reagents for easy use and storage; convenient direct-to-eye or smartphone-based readouts; and a one-pot variant of the multiplexed detection. To reduce reliance on proprietary reagents and enable sustainable use of such a technology in low- and middle-income countries, we locally produced and formulated our own recombinase polymerase amplification reaction and demonstrated its equivalent efficiency to commercial counterparts. Our tool—CRISPR-based detection for simultaneous COVID-19 diagnosis and variant surveillance that can be locally manufactured—may enable sustainable use of CRISPR diagnostics technologies for COVID-19 and other diseases in POC settings.
AU - Patchsung,M
AU - Homchan,A
AU - Aphicho,K
AU - Suraritdechachai,S
AU - Wanitchanon,T
AU - Pattama,A
AU - Sappakhaw,K
AU - Meesawat,P
AU - Wongsatit,T
AU - Athipanyasilp,A
AU - Jantarug,K
AU - Athipanyasilp,N
AU - Buahom,J
AU - Visanpattanasin,S
AU - Niljianskul,N
AU - Chaiyen,P
AU - Tinikul,R
AU - Wichukchinda,N
AU - Mahasirimongkol,S
AU - Sirijatuphat,R
AU - Angkasekwinai,N
AU - Crone,MA
AU - Freemont,PS
AU - Joung,J
AU - Ladha,A
AU - Abudayyeh,O
AU - Gootenberg,J
AU - Zhang,F
AU - Chewapreecha,C
AU - Chanarat,S
AU - Horthongkham,N
AU - Pakotiprapha,D
AU - Uttamapinant,C
DO - 10.1089/crispr.2022.0048
EP - 17
PY - 2022///
SN - 2573-1599
SP - 1
TI - A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance
T2 - The CRISPR Journal
UR - http://dx.doi.org/10.1089/crispr.2022.0048
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000884340600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
UR - https://www.liebertpub.com/doi/10.1089/crispr.2022.0048
VL - 6
ER -